Introduction
Protein methylation is recently considered an important post-translational modification and is predominantly found on lysine and arginine residues. Lysine methylation involves the addition of one to three methyl groups on the amino acid's ε-amine group, to form mono-, di-or tri-methyllysine. Its function is best understood in histones (1) . With the exception of Dot1/DOT1L, all histone lysine methyltransferases (HKMTs) contain a SET domain of about 130 amino acids and so far nearly 40 SET domain-containing HKMTs or potential HKMTs have been identified (2) . While our knowledge of the physiological functions of histone lysine methyltransferases is growing, their involvement in human diseases including cancer is still not well understood.
Proliferating cell nuclear antigen (PCNA) is an evolutionally well conserved protein found in all eukaryotic species from yeast to humans, as well as in archaea. PCNA functions are related to vital cellular processes such as DNA replication, chromatin remodeling, DNA repair, sister-chromatid cohesion and cell-cycle control (3) . PCNA was originally reported as an antigen for autoimmune disease in SLE (systemic lupus erythematosus) patients, detected only in the proliferating cell populations (4) .
Thereafter it was shown that expression levels of PCNA during cell cycle are differential and associated with proliferation and transformation (5, 6) . In the following years, a number of experiments have been done to uncover the role of PCNA in DNA replication, and one of the first functions clarified was a sliding clamp for DNA polymerase δ (7, 8). Meanwhile, the progress in the field not only strengthened the importance of PCNA, but also even placed PCNA at the crossroad of many essential pathways. Importantly, PCNA is post-translationally modified in several ways, which affects its function. So far, it has been reported that PCNA is ubiquitinated, phosphorylated, acetylated and even SUMOylated (3) . One of the well-documented post-translational modifications of PCNA is ubiquitination. In response to DNA damage, PCNA is monoubiquitinated at the lysine 164 residue by the E2 Ub conjugated enzyme Rad6 and the E3 Ub ligase Rad18 (Rad6/Rad18 complex) (9). Rad18 not only binds to Rad6 and PCNA, but also to DNA (10). Thus, Rad18 recruits the ubiquitination machinery to the chromatin-bound target, PCNA. In addition to ubiquitination, it is estimated that approximately 6% of chromatin-bound PCNA is subjected to phosphorylation on Tyr 211 (11). It has been considered that phosphorylation of Tyr 211 on PCNA may stabilize chromatin-bound PCNA as opposed to polyubiquitination.
Furthermore, acetylation is another modification detected on PCNA (12) and in yeast, a poly-SUMOylation on PCNA has been described (13) . However, functions of lysine methylation on PCNA have never been elucidated.
In this study, we demonstrated that the histone methyltransferase SETD8 methylates Lys 248 on PCNA and regulates functions of PCNA in cancer cells. This is the first report to describe the significance of lysine methylation on PCNA. 
Materials and Methods

Cell
Tissue samples and RNA preparation
Bladder tissue samples and RNA preparation were described previously (14) (15) (16) (17) .
Uroplakin is a marker of urothelial differentiation and is preserved in up to 90% of epithelially derived tumors (18) . Use of tissues for this study was approved by 
Quantitative real-time PCR
Specific primers for all human GAPDH (housekeeping gene), SDH (housekeeping gene), SETD8 and PCNA were designed (Primer sequences in Supplementary Table S1 ).
PCR reactions were performed using the LightCycler ® 480 System (Roche Applied Science) following the manufacture's protocol.
siRNA transfection
siRNA oligonucleotide duplexes were purchased from SIGMA Genosys for targeting the human SETD8 transcript. siEGFP, siFFLuc and siNegative control (siNC), which is a mixture of three different oligonucleotide duplexes, were used as control siRNAs. The siRNA sequences are described in Supplementary 
SETD8 is overexpressed in various types of cancer and regulates the growth of cancer cells
In order to investigate roles of a histone lysine methyltransferase in human carcinogenesis, we had examined expression levels of several HKMTs in a small subset of clinical bladder cancer samples and found a significant difference in expression levels of SETD8 between normal and cancer cells (data not shown). We then analyzed 124 bladder cancer samples and 28 normal control samples, and confirmed the significant elevation of SETD8 expression in tumor cells compared with in normal cells (Supplementary Table S4 ). Expression levels partly correlated with the grade of malignancy in bladder cancer ( Supplementary Fig. S1A ). We also found overexpression of SETD8 in both non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC) (Fig. 1A) . Subsequent immunohistochemical analysis using anti-SETD8 antibody identified strong SETD8 staining mainly in the nuclei of malignant cells, but no staining in non-neoplastic tissues (Fig. 1B) . In addition, our expression profiling analysis indicated the up-regulation of SETD8 in chronic myelogenous leukemia (CML), hepatocellular carcinoma (HCC) and pancreatic cancer (Supplementary Fig. S2 and Table S5 ). Furthermore, a high level of SETD8 was identified in various cancer cell lines, compared with a normal lung cell line, SAEC ( Supplementary Fig. S3 ).
To investigate the role of SETD8 in the growth of cancer cells, we performed a knockdown experiment using two independent siRNAs against SETD8 (siSETD8#1 and #2) and two control siRNAs (siEGFP and siFFLuc). We transfected each of these siRNAs into SW780 bladder cancer cells and found that SETD8 expression was efficiently suppressed by either of the two different siRNAs targeting SETD8, compared with control siRNAs (Supplementary Fig. S1B ). Using the same siRNAs, we performed cell growth assays and found significant growth suppressive effects on one bladder cell line (SW780) and two lung cancer cell lines (RERF-LC-AI and SBC5) while no effect was observed when we used control siRNAs (Fig. 1C) . Detailed cell cycle analysis using flow cytometry indicated that the cell populations of cancer cells lacking SETD8 had a significant increase in the amount of S phase and sub-G 1 phase cells and a concomitant reduction in the proportion of G 1 cells (Fig. 1D) . Furthermore, we showed that in BrdU incorporation analysis, the amount of newly incorporated BrdU in cancer cells was significantly decreased after treatment with siSETD8 ( Fig. 1E) , implying that knockdown of SETD8 results in the retardation of DNA replication in cancer cells.
These results indicated that SETD8 might play an important role in the regulation of cancer cell growth, especially in S Phase, and knockdown of SETD8 would cause apoptosis of cancer cells.
SETD8 methylates lysine 248 of PCNA both in vitro and in vivo
As PCNA is known to be a key regulator of cell cycle progression and SETD8 is a component of the PCNA complex (19, 20), we examined the functional relationship between SETD8 and PCNA. Immunoprecipitation assay showed that 3xFLAG-tagged SETD8 bound endogenous PCNA ( Fig. 2A) . We also confirmed the interaction between endogenous PCNA and SETD8 proteins (Fig. 2B) ; endogenous SETD8 and PCNA proteins were co-localized in HeLa cells (Fig. 2C) . Immunoprecipitation using deletion mutants of SETD8 showed that its N-terminal region of SETD8 is essential for the binding to PCNA (Fig. 2D) , and this portion contains a PCNA-interacting protein (PIP) box ( Supplementary Fig. S4A ). Since histone methyltransferases have been found to methylate non-histone substrates, we evaluated a possibility of PCNA to be a substrate of SETD8. Firstly, we performed an in vitro methyltransferase assay and confirmed that PCNA was methylated in a dose-dependent manner (Fig. 2E) . The amino acid analysis detected a single lysine methylation site in PCNA following this reaction ( Supplementary Fig. S5 ). To verify in vivo SETD8-dependent PCNA methylation, we labeled 293T cells after transfection with FLAG-PCNA (WT) and HA-Mock or Supplementary Fig. S6A ). Subsequent LC-MS/MS analysis identified mono-methylation at lysine 248 on PCNA by SETD8 (Fig. 2F) . To validate this result, we constructed the plasmid (PCNA-K248A) that was designed to substitute lysine 248 of PCNA protein to alanine and performed in vitro methyltransferase assay (Supplementary Fig. S6B ). The intensity of the band corresponding to PCNA methylation in PCNA-K248A was significantly diminished compared with that of the wild-type PCNA (PCNA-WT). These data demonstrate that lysine 248, which is highly conserved in the PCNA ortholog from green alga to human ( Supplementary Fig. S4B ), is the primary target of SETD8-dependent methylation (Fig.   2G ). On the basis of this result, we generated an antibody against a methylated K248 synthetic peptide ( Supplementary Fig. S7A ) that showed high affinity and high specificity by ELISA ( Supplementary Fig. S7B ). Western-blot analysis using this antibody confirmed that it specifically recognizes K248-methylated PCNA ( Fig. 2H and Supplementary Fig. S7C and D), and this specific signal was dependent on the methyltransferase activity of SETD8 (Fig. 2I) . Importantly, the methyltransferase activity of N-terminal deleted SETD8 protein, which lacks the PIP-box domain, was significantly low compared with that of wild-type SETD8 protein (Fig. 2J ). This result indicates that the N-terminal region of SETD8 containing PIP-box domain seems to be important for SETD8-dependent PCNA methylation. This antibody was used to examine the methylation status of PCNA in vivo after treatment with siSETD8 ( Supplementary Fig. S8 ). Mono-methylation of PCNA at lysine 248 diminished after knockdown of SETD8 in SBC5 cells, implying SETD8-dependent PCNA K248 methylation occurs both in vitro and in vivo.
SETD8 stabilizes PCNA protein through the methylation of lysine 248
To clarify the physiological significance of PCNA methylation by SETD8, we examined protein expression levels of PCNA in SW780 cells 48 h after knockdown of SETD8 using two independent siRNAs (Fig. 3A) . Knockdown of SETD8 decreased PCNA protein, suggesting involvement of SETD8 in regulating PCNA stability in cancer cells. To further validate this result, we examined the cell cycle dependency of SETD8 and PCNA protein expression levels after aphidicolin synchronization (Fig. 3B) .
Intriguingly, when we treated with SETD8 siRNAs, PCNA protein expression decreased in both G 1 and S phases according to the levels of SETD8, indicating that SETD8 is likely to be a key regulator of PCNA protein expression at G 1 and S phases. Since quantitative real-time PCR analysis implied that PCNA mRNA level was not affected by treatment with siSETD8 ( Fig. 3B ), the regulation of PCNA expression by SETD8 was not at the transcriptional level but at the protein level. To examine that this regulation is mediated by SETD8-dependent methylation, we examined PCNA (WT) or PCNA (K248A) protein expression levels in 293T cells transfected with mock or SETD8 expression vectors after cycloheximide treatment. Although wild-type PCNA was significantly stabilized by SETD8 expression, methylation-inactive mutant PCNA (PCNA-K248A) was unstable (Fig. 3C ). Furthermore, we examined the PCNA stability in endogenous level after depletion of SETD8 and found that the degradation rate of PCNA in cells treated with siSETD8 more rapidly than siEGFP ( Supplementary Fig. S9 ).
Taken together, SETD8-dependent methylation is crucial for PCNA stabilization. Then we validated the effect of SETD8-dependent methylation on ubiquitination of PCNA proteins. The PCNA (WT) or PCNA (K248A) expression vector was co-transfected into 293T cells with a vector expressing either the full-length or N-terminal region of SETD8, and ubiquitination and methylation status of PCNA was examined (Fig. 3D ).
As we expected, the status of ubiquitination and methylation on PCNA showed the inverse co-relation. Hence, we consider that methylation of PCNA inhibited its ubiquitination. We also examined the phosphorylation status of tyrosine 211 on PCNA, which is known to influence the stability of PCNA (11) between methylation and phosphorylation status was observed (data not shown). These data show that PCNA protein is stabilized through inhibition of the ubiquitination by its SETD8-dependent methylation.
Methylation of lysine 248 on PCNA affects its interaction with FEN1
We performed immunoprecipitation analysis to further investigate the significance of PCNA methylation, using wild-type and methylation-inactive mutant PCNA proteins, and identified a partner protein, FEN1, which interacted with PCNA in a methylation-dependent manner. Methylation of PCNA significantly enhanced the interaction between PCNA and FEN1 ( replication foci in cells when PCNA was a wild type. However, FEN1 was unable to localize to the foci in cells in which methylation-inactive mutant was present (Fig. 4C ).
These data suggest that PCNA methylation is important for regulation of FEN1's subnuclear localization. Since phosphorylation of FEN1 has been shown to abolish its PCNA interaction (25), we examined FEN1 phosphorylation status in cells expressing wild-type and methylation-inactive mutant PCNA, but found no significant difference in phosphorylation status of FEN1 between wild-type and methylation-inactive mutant PCNA expressing cells (Fig. 4D ). This implies that the different affinity between PCNA and FEN1 appear to be regulated not by phosphorylation status of FEN1 and but by methylation status of PCNA (as shown in Fig. 4A and C) . Furthermore, an Okazaki fragment maturation assay was performed, using the dNTP mixture containing We then compared the methylation of endogenous PCNA in normal and cancer cell lines. PCNA was significantly methylated in various types of cancer cell lines while no detectable level of PCNA methylation was found in normal cell lines (Fig. 5A) . We subsequently conducted the immunopathological analysis on clinical lung tissues, analyzing the correlation between SETD8 and PCNA protein expression levels ( Fig.   5B ). Clinical information and staining patterns of clinical tissues are described in Table   1 and Supplementary Table S6 . We found a correlation factor (ρ) of 0.55378 with P value of 2.068 x 10 -6 (by Spearman's correlation coefficient) in a cohort of 64 cases ( 
consistent with our findings which suggest that these abnormalities is likely to be caused by dysfunction of the PCNA protein.
PCNA is also considered to be the crucial factor in maintaining the balance between survival versus cell death. For instance, PCNA displays an apoptotic activity through interaction with proteins belonging to the Gadd45 family (Gadd45, Myd118 and CR6), which was involved in growth control, apoptosis and DNA repair (39, 40). Lack of SETD8 induces an increase of the sub-G 1 population of cancer cells (Fig.1D) , so it is possible that apoptosis may be induced by SETD8 depletion through dysfunction of PCNA. Furthermore, we clarified that methylation of PCNA is critical for the interaction with FEN1. It has been reported that FEN1 forms distinct protein complexes for DNA replication and repair. Through its interaction with PCNA, FEN1 is recruited to the replication foci for RNA primer removal and to repair sites for DNA base excision repair (41) . Recently, the FEN1-PCNA interaction has been implicated in coordinating the sequential action of polymerase δ (Pol δ), FEN1 and DNA ligase 1 In conclusion, as expression levels of SETD8 in normal tissues are significantly low ( Supplementary Fig. S13 ), an inhibitor targeting its enzymatic activity might be an effective drug for cancer therapy. Further functional analysis will explore the 
